Search

Displaying results 1641 - 1650 of 10000 in total
  1. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    Prostate cancer is the most common non-cutaneous malignancy affecting men in North America[A235344] - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent … levels roughly 1000-fold greater than elsewhere in the body, and even higher in prostate cancer tissue.

  2. Drug

    Alclofenac

    go.drugbank.com/drugs/DB13167
    ApprovedWithdrawn

    It was withdrawn from the market in the United Kingdom in 1979.

  3. Drug

    Evening primrose oil

    go.drugbank.com/drugs/DB11358
    ApprovedNutraceutical

    In its composition it presents some fatty acids such as [DB00132] and [DB13854]. … [L2845] By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements.[L1113] By the EMA, evening primrose oil is approved in herbal preparations.[L2851]

    Mixtures: PRIM E CAPSULE, Evening Primrose Oil With Vitamin ECategories: Complex Mixtures
  4. Drug

    Succimer

    go.drugbank.com/drugs/DB00566
    ApprovedInvestigational

    A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. … Lubiprostone is a medication used in the management of idiopathic chronic constipation.

    Categories: Prostaglandins E
  6. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency. … [Peginterferon Alfa-2a]) in Patients With CHD.

  7. Drug

    Urea

    go.drugbank.com/drugs/DB03904
    ApprovedInvestigational

    It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. … A compound formed in the liver from ammonia produced by the deamination of amino acids.

    Mixtures: HYDROCORTISONE 1% ET UREA 5% CREAM, Canesten Bifonazol comp. - Salbe + NagelsetProducts: EUREA CREAM
  8. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.

    Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidine
  9. Drug

    Human C1-esterase inhibitor

    go.drugbank.com/drugs/DB06404
    ApprovedInvestigational

    [L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]

    Categories: Drugs Used in Hereditary Angioedema
  10. Target

    Proteasome subunit beta type-8

    go.drugbank.com/bio_entities/BE0004739
    TargetHumans

    The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic

    Synonyms: Multicatalytic endopeptidase complex subunit C13